Company Showcase Oncology

Cellestia Biotech

Cellestia is a clinical-stage biopharma company targeting cancer at the level of gene transcription. Our lead compound, CB-103, is well tolerated and showing first signs of activity in an ongoing Phase 1 trial.

Cellestia Biotech于2014年成立,总部设在瑞士巴塞尔,由瑞士洛桑联邦理工学院(EPFL)拆分出来。Cellestia的主要开发化合物是CB-103,这是一种新型的一流口服pan-NOTCH抑制剂,用于治疗患有NOTCH依赖性白血病、淋巴瘤和实体瘤的患者。